RxDoctor Payments DataLook up a doctor →

Erik Alexander, MD

Dermatology · Milwaukee, WINPI 1770748303

Payments from drug & device makers

$25,480in general payments, 2019–2025

Across 1,519 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Sun Pharmaceutical Industries Inc.$4K
  • Johnson & Johnson$2K
  • Lilly USA, LLC$2K
  • Sanofi$2K
  • Amgen$2K
  • plus $10K from 28 others

What the payments were for

  • Food & beverage$24,73997%
  • Education$7423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,480 in reported general payments places this provider in the 90th percentile of 260 dermatology providers in Wisconsin.

See all dermatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$39,078
Medicare patients
151
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab50$512,897
RinvoqUpadacitinib63$443,450
Dupixent PenDupilumab60$238,348
Cosentyx Unoready PenSecukinumab27$201,401
Taltz AutoinjectorIxekizumab25$172,418
EnbrelEtanercept13$112,630
CibinqoAbrocitinib15$84,977
OpzeluraRuxolitinib Phosphate15$30,733
Clobetasol Propionate451$18,379
Ivermectin14$17,622
Tretinoin78$6,664
Azelaic Acid33$4,004
Mycophenolate Mofetil38$3,642
Fluocinolone AcetonideFluocinolone/Shower Cap49$3,455
Halobetasol Propionate45$3,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$4,010$443,45063 claims
AmgenEnbrel$1,618$112,63013 claims
PfizerCibinqo$1,533$84,97715 claims
Incyte CorporationOpzelura$494$30,73315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 260 dermatology providers in Wisconsin.

Other dermatology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →